Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Filippo de Braud, Christophe Dooms, Rebecca S Heist, Celeste Lebbe, Martin Wermke, Anas Gazzah, Dirk Schadendorf, Piotr Rutkowski, Jürgen Wolf, Paolo A Ascierto, Ignacio Gil-Bazo, Shumei Kato, Maria Wolodarski, Meredith McKean, Eva Muñoz Couselo, Martin Sebastian, Armando Santoro, Vesselina Cooke, Luca Manganelli, Kitty Wan, Anil Gaur, Jaeyeon Kim, Giordano Caponigro, Xuân-Mai Couillebault, Helen Evans, Catarina D Campbell, Sumit Basu, Michele Moschetta, Adil Daud
PURPOSE: No approved targeted therapy for the treatment of patients with neuroblastoma RAS viral (v-ras) oncogene homolog ( NRAS )-mutant melanoma is currently available. PATIENTS AND METHODS: In this phase Ib escalation/expansion study (ClinicalTrials.gov identifier: NCT02974725), the safety, tolerability, and preliminary antitumor activity of naporafenib (LXH254), a BRAF/CRAF protein kinases inhibitor, were explored in combination with trametinib in patients with advanced/metastatic KRAS- or BRAF -mutant non-small-cell lung cancer (escalation arm) or NRAS -mutant melanoma (escalation and expansion arms)...
March 22, 2023: Journal of Clinical Oncology
#2
EDITORIAL
Hannah D McManus, Andrew J Armstrong
No abstract text is available yet for this article.
March 22, 2023: Journal of Clinical Oncology
#3
JOURNAL ARTICLE
Manali S Phadke, Keiran S M Smalley
No abstract text is available yet for this article.
March 22, 2023: Journal of Clinical Oncology
#4
JOURNAL ARTICLE
Jennifer K Plichta, Samantha M Thomas, Daniel F Hayes, Mariana Chavez-MacGregor, Kimberly Allison, Jennifer de Los Santos, Amy M Fowler, Armando E Giuliano, Priyanka Sharma, Benjamin D Smith, Elizabeth van Eycken, Stephen B Edge, Gabriel N Hortobagyi
PURPOSE: Given the heterogeneity and improvement in outcomes for metastatic breast cancer (MBC), we developed a staging system that refines prognostic estimates for patients with metastatic cancer at the time of initial diagnosis, de novo MBC (dnMBC), on the basis of survival outcomes and disease-related variables. METHODS: Patients with dnMBC (2010-2016) were selected from the National Cancer Database (NCDB). Recursive partitioning analysis (RPA) was used to group patients with similar overall survival (OS) on the basis of clinical T category, grade, estrogen receptor (ER), progesterone receptor, human epidermal growth factor receptor 2, histology, organ system site of metastases (bone-only, brain-only, visceral), and number of organ systems involved...
March 21, 2023: Journal of Clinical Oncology
#5
JOURNAL ARTICLE
Roger Olofsson Bagge, Axel Nelson, Amir Shafazand, Charlotta All-Eriksson, Christian Cahlin, Nils Elander, Hildur Helgadottir, Jens Folke Kiilgaard, Sara Kinhult, Ingrid Ljuslinder, Jan Mattsson, Magnus Rizell, Malin Sternby Eilard, Gustav J Ullenhag, Jonas A Nilsson, Lars Ny, Per Lindnér
PURPOSE: About half of patients with metastatic uveal melanoma present with isolated liver metastasis, in whom the median survival is 6-12 months. The few systemic treatment options available only moderately prolong survival. Isolated hepatic perfusion (IHP) with melphalan is a regional treatment option, but prospective efficacy and safety data are lacking. METHODS: In this multicenter, randomized, open-label, phase III trial, patients with previously untreated isolated liver metastases from uveal melanoma were randomly assigned to receive a one-time treatment with IHP with melphalan or best alternative care (control group)...
March 20, 2023: Journal of Clinical Oncology
#6
LETTER
Shang-Xiao Huang, Peng-Hui Luo, Han-Lei Wang, Dun-Chang Mo, Jian-Feng Huang
No abstract text is available yet for this article.
March 20, 2023: Journal of Clinical Oncology
#7
LETTER
Ashwin P Patel
No abstract text is available yet for this article.
March 20, 2023: Journal of Clinical Oncology
#8
(no author information available yet)
No abstract text is available yet for this article.
March 20, 2023: Journal of Clinical Oncology
#9
(no author information available yet)
No abstract text is available yet for this article.
March 20, 2023: Journal of Clinical Oncology
#10
JOURNAL ARTICLE
Vivek Subbiah, Razelle Kurzrock
No abstract text is available yet for this article.
March 17, 2023: Journal of Clinical Oncology
#11
EDITORIAL
Marcelo Coca Perraillon, Ya-Chen Tina Shih
No abstract text is available yet for this article.
March 17, 2023: Journal of Clinical Oncology
#12
JOURNAL ARTICLE
Elisabetta Sauta, Marie Robin, Matteo Bersanelli, Erica Travaglino, Manja Meggendorfer, Lin-Pierre Zhao, Juan Carlos Caballero Berrocal, Claudia Sala, Giulia Maggioni, Massimo Bernardi, Carmen Di Grazia, Luca Vago, Giulia Rivoli, Lorenza Borin, Saverio D'Amico, Cristina Astrid Tentori, Marta Ubezio, Alessia Campagna, Antonio Russo, Daniele Mannina, Luca Lanino, Patrizia Chiusolo, Luisa Giaccone, Maria Teresa Voso, Marta Riva, Esther Natalie Oliva, Matteo Zampini, Elena Riva, Olivier Nibourel, Marilena Bicchieri, Niccolo' Bolli, Alessandro Rambaldi, Francesco Passamonti, Victor Savevski, Armando Santoro, Ulrich Germing, Shahram Kordasti, Valeria Santini, Maria Diez-Campelo, Guillermo Sanz, Francesc Sole, Wolfgang Kern, Uwe Platzbecker, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Gastone Castellani, Matteo Giovanni Della Porta
PURPOSE: Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve the prediction of clinical outcome of the currently available tool (Revised International Prognostic Scoring System [IPSS-R]). We aimed to provide an extensive validation of IPSS-M. METHODS: A total of 2,876 patients with primary MDS from the GenoMed4All consortium were retrospectively analyzed...
March 17, 2023: Journal of Clinical Oncology
#13
JOURNAL ARTICLE
Mikael Eriksson, Kamila Czene, Celine Vachon, Emily F Conant, Per Hall
PURPOSE: Image-derived artificial intelligence-based short-term risk models for breast cancer have shown high discriminatory performance compared with traditional lifestyle/familial-based risk models. The long-term performance of image-derived risk models has not been investigated. METHODS: We performed a case-cohort study of 8,604 randomly selected women within a mammography screening cohort initiated in 2010 in Sweden for women age 40-74 years. Mammograms, age, lifestyle, and familial risk factors were collected at study entry...
March 17, 2023: Journal of Clinical Oncology
#14
JOURNAL ARTICLE
Margret Merino, Yvette Kasamon, Marc Theoret, Richard Pazdur, Paul Kluetz, Nicole Gormley
No abstract text is available yet for this article.
March 17, 2023: Journal of Clinical Oncology
#15
JOURNAL ARTICLE
Leire Burgos, Luis-Esteban Tamariz-Amador, Noemi Puig, Maria-Teresa Cedena, Camila Guerrero, Tomas Jelínek, Sarah Johnson, Paolo Milani, Lourdes Cordon, Jose J Perez, Marta Lasa, Rosalinda Termini, Albert Oriol, Miguel-Teodoro Hernandez, Luis Palomera, Rafael Martinez-Martinez, Javier de la Rubia, Felipe de Arriba, Rafael Rios, Maria-Esther Gonzalez, Mercedes Gironella, Valentin Cabañas, Maria Casanova, Isabel Krsnik, Albert Perez-Montaña, Verónica González-Calle, Paula Rodriguez-Otero, Vladimir Maisnar, Roman Hajek, Fritz Van Rhee, Victor Jimenez-Zepeda, Giovanni Palladini, Giampaolo Merlini, Alberto Orfao, Javier de la Cruz, Joaquin Martinez-Lopez, Juan-Jose Lahuerta, Laura Rosiñol, Joan Blade, Maria-Victoria Mateos, Jesus F San-Miguel, Bruno Paiva
PURPOSE: The existence of patients with multiple myeloma (MM) and light-chain (AL) amyloidosis who present with a monoclonal gammopathy of undetermined significance (MGUS)-like phenotype has been hypothesized, but methods to identify this subgroup are not standardized and its clinical significance is not properly validated. PATIENTS AND METHODS: An algorithm to identify patients having MGUS-like phenotype was developed on the basis of the percentages of total bone marrow (BM) plasma cells (PC) and of clonal PC within the BM PC compartment, determined at diagnosis using flow cytometry in 548 patients with MGUS and 2,011 patients with active MM...
March 17, 2023: Journal of Clinical Oncology
#16
JOURNAL ARTICLE
Marie Flannery, Eva Culakova, Supriya Mohile
No abstract text is available yet for this article.
March 17, 2023: Journal of Clinical Oncology
#17
LETTER
Takahiro Kaneko, Akihiko Shimomura, Chikako Shimizu
No abstract text is available yet for this article.
March 17, 2023: Journal of Clinical Oncology
#18
JOURNAL ARTICLE
Michal Sarfaty, Mahdi Golkaram, Samuel A Funt, Hikmat Al-Ahmadie, Shannon Kaplan, Fan Song, Ashley Regazzi, Vladimir Makarov, Fengshen Kuo, Irina Ostrovnaya, Venkatraman Seshan, Chen Zhao, Benjamin Greenbaum, Li Liu, Jonathan E Rosenberg, Timothy A Chan
PURPOSE: Immune checkpoint blockade (ICB) therapy has significantly improved clinical outcomes in bladder cancer. Identification of correlates of benefit is critical to select appropriate therapy for individual patients. METHODS: To reveal genetic variables associated with benefit from ICB, we performed whole-exome sequencing on tumor specimens from 88 patients with advanced bladder cancer treated with ICB. RESULTS: We identified several genetic factors that correlated with progression-free and overall survival after ICB therapy including ARID1A mutation, tumor mutational burden, intratumoral heterogeneity, the ratio of nonsynonymous to synonymous mutations in the immunopeptidome (immune dN/dS), and tumor cell purity...
March 16, 2023: Journal of Clinical Oncology
#19
EDITORIAL
Implementing Evidence-Based Tobacco Treatment Interventions in Oncology to Achieve Optimal Outcomes.
Jamie L Studts, Heidi A Hamann
No abstract text is available yet for this article.
March 16, 2023: Journal of Clinical Oncology
#20
JOURNAL ARTICLE
Jennifer I Vidrine, Steven K Sutton, David W Wetter, Ya-Chen Tina Shih, Lois M Ramondetta, Linda S Elting, Joan L Walker, Katie M Smith, Summer G Frank-Pearce, Yisheng Li, Sarah R Jones, Darla E Kendzor, Vani N Simmons, Damon J Vidrine
PURPOSE: Women who smoke and have a history of cervical intraepithelial neoplasia (CIN) or cervical cancer represent a vulnerable subgroup at elevated risk for recurrence, poorer cancer treatment outcomes, and decreased quality of life. The purpose of this study was to evaluate the long-term efficacy of Motivation And Problem Solving (MAPS), a novel treatment well-suited to meeting the smoking cessation needs of this population. METHODS: Women who were with a history of CIN or cervical cancer, age 18 years and older, spoke English or Spanish, and reported current smoking (≥100 lifetime cigarettes plus any smoking in the past 30 days) were eligible...
March 15, 2023: Journal of Clinical Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
